Review finds type 2 diabetes linked to 53% higher risk of Alzheimer's disease
A systematic review and meta-analysis led by Australia's Curtin University found that people with type 2 diabetes face a markedly higher risk of Alzheimer's disease. Their adjusted relative risk was 53% higher than for people without the condition.

A research review led by Curtin University in Australia has concluded that people with type 2 diabetes are at significantly higher risk of developing Alzheimer's disease, a neurodegenerative condition that impairs memory and thinking. The results sharpen the picture of the link between the two conditions, showing both how much the risk rises and how often new cases appear.
The researchers carried out a systematic review and meta-analysis that pooled data from 40 studies. They estimated that among every 1,000 people with type 2 diabetes, about 4.7 would develop Alzheimer's disease within a year. A separate analysis showed that the adjusted relative risk of Alzheimer's was 53% higher in people with type 2 diabetes than in those without it.
What sets this review apart
Study author Dr. Emmanuel Adewuyi, an NHMRC Investigator Fellow at the Curtin School of Population Health (NHMRC is Australia's National Health and Medical Research Council), said the findings give a more precise understanding of Alzheimer's risk in people with type 2 diabetes.
Earlier reviews often grouped together several forms of diabetes or dementia. This one focused specifically on type 2 diabetes and Alzheimer's disease, and it also measured how frequently people with diabetes went on to develop the illness.
"Relative risk tells us how two groups compare, while incidence tells us how often new cases occur: putting those numbers together gives us a clearer picture of the burden of Alzheimer's disease among people living with type 2 diabetes," Adewuyi said.
The study, titled "Incidence and risk of Alzheimer's disease in individuals with type 2 diabetes: a systematic review and meta-analysis," was published in the journal Alzheimer's Research & Therapy.


